PANAVANCE

Panavance Therapeutics is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (also known as GP-2250). Panavance, a US Delaware company located in Berwyn, PA, was founded in 2021 as wholly owned carve out of the Geistlich group, a family-owned Swiss company, to focus on misetionamide and the oncology business.​... Panavance is currently conducting a multicenter phase 1 dose escalation trial in four US clinical sites. The company plans to initiate a clinical trial of misetionamide for the treatment of platinum-resistant ovarian cancer and a clinical trial as a first-line maintenance therapy for non-BRCA mutated pancreatic cancer patients, a population for which there are no FDA approved drugs. Extensive preclinical studies have demonstrated that misetionamide's broadly anti-neoplastic MOA has the potential to be effective in additional tumor types, including melanoma, squamous cell, breast, and colorectal cancers.​... We are focused..

Also known as: Panavance Therapeutics, Panavance Therapeutics Inc.